Ketamine as a Novel Drug for Depression Treatment.
Journal
Psychiatria Danubina
ISSN: 0353-5053
Titre abrégé: Psychiatr Danub
Pays: Croatia
ID NLM: 9424753
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
20
12
2021
pubmed:
21
12
2021
medline:
24
12
2021
Statut:
ppublish
Résumé
Depression is one of the most common mental disorders. Currently used antidepressants, acting on the monoaminergic system, are insufficient for depression treatment. In recent years, potential application of NMDA receptor modulators in the treatment of drug-resistant depression has gained attention. Administration of ketamine, being a non-competitive NMDA receptor antagonist, contributes to a faster remission of symptoms. The aim of this paper is to review current studies on the use of ketamine in the treatment of drug-resistant depression, compare results of various administration methods - intravenous, intranasal or oral, as well as compare its effectiveness with that of other antidepressants. Numerous studies show the drug is effective and well tolerated, particularly in patients with increased suicidal thoughts. However, there are concerns on increasing tolerance to the drug and the possibility of implementing a long-term treatment. Oral and intranasal forms of the drug are particularly promising due to their non-invasiveness and ability to self-administer. In March 2019, S-ketamine nasal spray was registered by the FDA for the treatment of drug-resistant depression.
Sections du résumé
BACKGROUND
BACKGROUND
Depression is one of the most common mental disorders. Currently used antidepressants, acting on the monoaminergic system, are insufficient for depression treatment. In recent years, potential application of NMDA receptor modulators in the treatment of drug-resistant depression has gained attention. Administration of ketamine, being a non-competitive NMDA receptor antagonist, contributes to a faster remission of symptoms.
SUBJECTS AND METHODS
METHODS
The aim of this paper is to review current studies on the use of ketamine in the treatment of drug-resistant depression, compare results of various administration methods - intravenous, intranasal or oral, as well as compare its effectiveness with that of other antidepressants.
RESULTS
RESULTS
Numerous studies show the drug is effective and well tolerated, particularly in patients with increased suicidal thoughts. However, there are concerns on increasing tolerance to the drug and the possibility of implementing a long-term treatment.
CONCLUSION
CONCLUSIONS
Oral and intranasal forms of the drug are particularly promising due to their non-invasiveness and ability to self-administer. In March 2019, S-ketamine nasal spray was registered by the FDA for the treatment of drug-resistant depression.
Identifiants
pubmed: 34928893
doi: 10.24869/psyd.2021.468
doi:
Substances chimiques
Antidepressive Agents
0
Pharmaceutical Preparations
0
Ketamine
690G0D6V8H
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM